Archives of Clinical Infectious Diseases

Published by: Kowsar

Tenofovir Alafenamide: A New Drug With Various Ambiguous Aspects in Treatment of Chronic Hepatitis B Infection

Soheil Tavakolpour 1 , Mohammad Darvishi 2 and Shahnaz Sali 1 , *
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Aerospace and Subaquatic Medicine, Infectious Diseases and Tropical Medicine Research Center, AJA University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: 14 (1); e65343
  • Published Online: January 8, 2019
  • Article Type: Letter
  • Received: June 14, 2018
  • Revised: June 14, 2018
  • Accepted: August 5, 2018
  • DOI: 10.5812/archcid.65343

To Cite: Tavakolpour S, Darvishi M, Sali S. Tenofovir Alafenamide: A New Drug With Various Ambiguous Aspects in Treatment of Chronic Hepatitis B Infection, Arch Clin Infect Dis. Online ahead of Print ; 14(1):e65343. doi: 10.5812/archcid.65343.

Copyright © 2019, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Mardani M. Hepatitis B and C and the role of non-specialists on disease elimination. Arch Clin Infect Dis. 2016;11(4):1-2. doi: 10.5812/archcid.42734.
  • 2. Tavakolpour S, Mirsafaei HS, Behjati SE, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos (t) ide analogues therapy. Immunology lett. 2017;190:206-12. doi: 10.1016/j.imlet.2017.08.003.
  • 3. Wilson EMP, Tang L, Kottilil S. Eradication strategies for chronic hepatitis B infection. Clin Infect Dis. 2016;62(suppl_4):S318-25. doi: 10.1093/cid/ciw044.
  • 4. Tavakolpour S, Alavian SM, Sali S. Manipulation of regulatory cells' responses to treatments for chronic hepatitis B virus infection. Hepat Mon. 2016;16(6). e37927. doi: 10.5812/hepatmon.37927. [PubMed: 27630728]. [PubMed Central: PMC5010887].
  • 5. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-83. doi: 10.1002/hep.28156. [PubMed: 26566064]. [PubMed Central: PMC5987259].
  • 6. Buti M, Riveiro-Barciela M, Esteban R. Tenofovir alafenamide fumarate: A new tenofovir prodrug for the treatment of chronic hepatitis B infection. J Infect Dis. 2017;216(suppl_8):S792-6. doi: 10.1093/infdis/jix135. [PubMed: 29156043].
  • 7. Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185-95. doi: 10.1016/S2468-1253(16)30024-3. [PubMed: 28404091].
  • 8. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. [PubMed: 28404092].
  • 9. Kaufman MB. Pharmaceutical approval update. P T. 2017;42(8):502-4. [PubMed: 28781502]. [PubMed Central: PMC5521297].
  • 10. Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672-81. doi: 10.1016/j.jhep.2017.11.039. [PubMed: 29756595].
  • 11. No Author Listed. Food and drug administration. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208464s000lbl.pdf.
  • 12. Agarwal K, Fung S, Seto WK, Lim YS, Gane E, Janssen HL, et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): Efficacy and safety results at week 96. J Hepatol. 2017;66(1). S478. doi: 10.1016/S0168-8278(17)31347-8.
  • 13. Tavakolpour S, Darvishi M, Mirsafaei HS, Ghasemiadl M. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: A systematic review. Infect Dis (Lond). 2018;50(2):95-106. doi: 10.1080/23744235.2017.1384957. [PubMed: 29020844].
  • 14. Tavakolpour S, Alavian SM, Sali S. Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: A comprehensive review-screened. Hepat Mon. 2016;16(4). e35810. doi: 10.5812/hepatmon.35810. [PubMed: 27257429]. [PubMed Central: PMC4887960].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments